Takeshi Miyamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takeshi Miyamoto has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Morio Matsumoto
Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan
39 shared publicationsYuiko Sato
Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan
39 shared publicationsTami Kobayashi
Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan
37 shared publicationsKana Miyamoto
Department of Orthopedic Surgery, Kumamoto University, Kumamoto, Japan
34 shared publicationsMasaya Nakamura
Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan
29 shared publicationsYoshiaki Toyama
Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan
19 shared publications
Latest Publications
- Open Access
- 26 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Bezafibrate attenuates immobilization-induced muscle atrophy in mice
Muscle atrophy due to fragility fractures or frailty worsens not only activity of daily living and healthy life expectancy, but decreases life expectancy. Although several therapeutic agents for muscle atrophy have been investigated, none is yet in clinical use. Here we report that bezafibrate, a drug used to treat hyperlipidemia, can reduce immobilization-induced muscle atrophy in mice. Specifically, we used a drug repositioning approach to screen 144 drugs already utilized clinically for their ability to inhibit serum starvation-induced elevation of Atrogin-1, a factor related to muscle atrophy, in myotubes in vitro. Two candidates were selected, and here we demonstrate that one of them, bezafibrate, significantly reduced muscle atrophy in an in vivo model of muscle atrophy induced by leg immobilization. In gastrocnemius muscle, immobilization reduced muscle weight by an average of ~ 17.2%, and bezafibrate treatment prevented ~ 40.5% of that atrophy. In vitro, bezafibrate significantly inhibited expression of the inflammatory cytokine Tnfa in lipopolysaccharide-stimulated RAW264.7 cells, a murine macrophage line. Finally, we show that expression of Tnfa and IL-1b is induced in gastrocnemius muscle in the leg immobilization model, an activity significantly antagonized by bezafibrate administration in vivo. We conclude that bezafibrate could serve as a therapeutic agent for immobilization-induced muscle atrophy.
- 26 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessBezafibrate attenuates immobilization-induced muscle atrophy in mice
Muscle atrophy due to fragility fractures or frailty worsens not only activity of daily living and healthy life expectancy, but decreases life expectancy. Although several therapeutic agents for muscle atrophy have been investigated, none is yet in clinical use. Here we report that bezafibrate, a drug used to treat hyperlipidemia, can reduce immobilization-induced muscle atrophy in mice. Specifically, we used a drug repositioning approach to screen 144 drugs already utilized clinically for their ability to inhibit serum starvation-induced elevation of Atrogin-1, a factor related to muscle atrophy, in myotubes in vitro. Two candidates were selected, and here we demonstrate that one of them, bezafibrate, significantly reduced muscle atrophy in an in vivo model of muscle atrophy induced by leg immobilization. In gastrocnemius muscle, immobilization reduced muscle weight by an average of ~ 17.2%, and bezafibrate treatment prevented ~ 40.5% of that atrophy. In vitro, bezafibrate significantly inhibited expression of the inflammatory cytokine Tnfa in lipopolysaccharide-stimulated RAW264.7 cells, a murine macrophage line. Finally, we show that expression of Tnfa and IL-1b is induced in gastrocnemius muscle in the leg immobilization model, an activity significantly antagonized by bezafibrate administration in vivo. We conclude that bezafibrate could serve as a therapeutic agent for immobilization-induced muscle atrophy.
- 13 March 2023
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 41 (2) , 182-192
Low energy availability reduces bone mass and gonadal function in male mice
Introduction In women, the female athlete triad, marked by low energy availability, functional hypothalamic amenorrhea and osteoporosis, is a recognized risk for stress fractures. Stress injuries also occur in men, but by contrast risks and mechanisms underlying them are less characterized. Materials and methods 5 week-old wild-type male mice were fed ad libitum (ad) or subjected to 60% food restriction (FR) for five weeks. In both groups, some mice were allowed access to an exercise wheel in cages to allow voluntary wheel running (ex) and/or treated with active vitamin D analogues. Mice were sacrificed and analyzed at 10 weeks of age. Result Male FR mice exhibited significantly reduced testicle weight, serum testosterone levels and bone mass. Such bone losses in FR male mice were enhanced by exercise. Histological analysis revealed that both bone-resorbing and -forming activities were significantly reduced in FR or FR plus exercise (FR + ex) mice, mimicking a state of low bone turnover. Significantly reduced bone mass in FR or FR + ex male mice was significantly rescued by treatment with active vitamin D analogues, with significant restoration of osteoblastic activities. Serum levels of insulin-like growth factor I (IGF-I), which is critical for bone remodeling, were significantly lower in FR versus control male mice. Conclusions Low energy availability puts men at risk for stress injuries as well, and low energy availability is upstream of gonadal dysfunction and osteoporosis in males. Active vitamin D analogues could serve as therapeutic or preventive options for stress injuries in men.
- 13 March 2023
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 41 (2) , 182-192
Low energy availability reduces bone mass and gonadal function in male mice
Introduction In women, the female athlete triad, marked by low energy availability, functional hypothalamic amenorrhea and osteoporosis, is a recognized risk for stress fractures. Stress injuries also occur in men, but by contrast risks and mechanisms underlying them are less characterized. Materials and methods 5 week-old wild-type male mice were fed ad libitum (ad) or subjected to 60% food restriction (FR) for five weeks. In both groups, some mice were allowed access to an exercise wheel in cages to allow voluntary wheel running (ex) and/or treated with active vitamin D analogues. Mice were sacrificed and analyzed at 10 weeks of age. Result Male FR mice exhibited significantly reduced testicle weight, serum testosterone levels and bone mass. Such bone losses in FR male mice were enhanced by exercise. Histological analysis revealed that both bone-resorbing and -forming activities were significantly reduced in FR or FR plus exercise (FR + ex) mice, mimicking a state of low bone turnover. Significantly reduced bone mass in FR or FR + ex male mice was significantly rescued by treatment with active vitamin D analogues, with significant restoration of osteoblastic activities. Serum levels of insulin-like growth factor I (IGF-I), which is critical for bone remodeling, were significantly lower in FR versus control male mice. Conclusions Low energy availability puts men at risk for stress injuries as well, and low energy availability is upstream of gonadal dysfunction and osteoporosis in males. Active vitamin D analogues could serve as therapeutic or preventive options for stress injuries in men.
- Open Access
- 1 November 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-11
An ionic silver coating prevents implant-associated infection by anaerobic bacteria in vitro and in vivo in mice
Currently, implants are utilized clinically for bone transplant procedures. However, if infectious osteomyelitis occurs at implant sites, removal of bacteria can be challenging. Moreover, altered blood flow at peri-implant infectious sites can create an anaerobic environment, making it more difficult to treat infection with antibiotics. Thus, it would be beneficial if implants could be modified to exhibit antibacterial activity, even in anaerobic conditions. Here, we show antibacterial activity of silver ions coated on titanium rods, even against the anaerobic bacteria Porphyromonas gingivalis (P. gingivalis), both in vitro and in vivo. Specifically, we implanted silver-coated or control uncoated titanium rods along with P. gingivalis in mouse femoral bone BM cavities and observed significantly inhibited P. gingivalis infection with silver-coated compared with non-coated rods, based on in vivo bio-imaging. Osteonecrosis by infectious osteomyelitis and elevation of the inflammatory factors C-reactive protein and IL-6 promoted by P. gingivalis s were also significantly reduced in the presence of silver-coated rods. Overall, our study indicates that silver ion coating of an implant represents a therapeutic option to prevent associated infection, even in anaerobic conditions or against anaerobic bacteria.
- 1 November 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-11
Open AccessAn ionic silver coating prevents implant-associated infection by anaerobic bacteria in vitro and in vivo in mice
Currently, implants are utilized clinically for bone transplant procedures. However, if infectious osteomyelitis occurs at implant sites, removal of bacteria can be challenging. Moreover, altered blood flow at peri-implant infectious sites can create an anaerobic environment, making it more difficult to treat infection with antibiotics. Thus, it would be beneficial if implants could be modified to exhibit antibacterial activity, even in anaerobic conditions. Here, we show antibacterial activity of silver ions coated on titanium rods, even against the anaerobic bacteria Porphyromonas gingivalis (P. gingivalis), both in vitro and in vivo. Specifically, we implanted silver-coated or control uncoated titanium rods along with P. gingivalis in mouse femoral bone BM cavities and observed significantly inhibited P. gingivalis infection with silver-coated compared with non-coated rods, based on in vivo bio-imaging. Osteonecrosis by infectious osteomyelitis and elevation of the inflammatory factors C-reactive protein and IL-6 promoted by P. gingivalis s were also significantly reduced in the presence of silver-coated rods. Overall, our study indicates that silver ion coating of an implant represents a therapeutic option to prevent associated infection, even in anaerobic conditions or against anaerobic bacteria.
- Open Access
- 2 September 2022
- Published by Springer Nature in Research Square
Low energy availability reduces bone mass and gonadal function in male mice
In women, the female athlete triad, marked by low energy availability, functional hypothalamic amenorrhea and osteoporosis, is a recognized risk for stress fractures. Stress injuries also occur in men, but by contrast risks and mechanisms underlying them are less characterized. Here we propose that low energy availability puts men at risk for stress injuries as well. Male low energy availability model mice, established by limiting food intake, exhibited significantly reduced testicle weight, serum testosterone levels and bone mass. Such losses in bone mass were enhanced by exercise in food-restricted (FR) male mice. Histological analysis revealed that both bone-resorbing and -forming activities were significantly reduced in FR or FR plus exercise (FR+ex) mice, mimicking a state of low bone turnover. Significantly reduced bone mass in FR or FR+ex male mice was significantly rescued by treatment with 1,25(OH)2D3 (1.25) or ED71 (ED), both active vitamin D analogues, with significant restoration of osteoblastic activities. Serum levels of insulin-like growth factor I (IGF-I), which activates osteoblastic activities and is critical for bone remodeling, were significantly lower in FR versus control male mice, but restored by administration of either of vitamin D analogue. However, administration of recombinant IGF-I did not rescue reduced bone mass in FR male mice, and administration of either active vitamin D analogue could increase bone mass even in IGF-I conditional knockout FR male mice. Taken together, conditions comparable to the female athlete triad are also a risk for male stress injuries, and low energy availability is upstream of gonadal dysfunction and osteoporosis in males. Active vitamin D analogues could serve as therapeutic or preventive options for stress injuries in men.
- 2 September 2022
- Published by Springer Nature in Research Square
Open AccessLow energy availability reduces bone mass and gonadal function in male mice
In women, the female athlete triad, marked by low energy availability, functional hypothalamic amenorrhea and osteoporosis, is a recognized risk for stress fractures. Stress injuries also occur in men, but by contrast risks and mechanisms underlying them are less characterized. Here we propose that low energy availability puts men at risk for stress injuries as well. Male low energy availability model mice, established by limiting food intake, exhibited significantly reduced testicle weight, serum testosterone levels and bone mass. Such losses in bone mass were enhanced by exercise in food-restricted (FR) male mice. Histological analysis revealed that both bone-resorbing and -forming activities were significantly reduced in FR or FR plus exercise (FR+ex) mice, mimicking a state of low bone turnover. Significantly reduced bone mass in FR or FR+ex male mice was significantly rescued by treatment with 1,25(OH)2D3 (1.25) or ED71 (ED), both active vitamin D analogues, with significant restoration of osteoblastic activities. Serum levels of insulin-like growth factor I (IGF-I), which activates osteoblastic activities and is critical for bone remodeling, were significantly lower in FR versus control male mice, but restored by administration of either of vitamin D analogue. However, administration of recombinant IGF-I did not rescue reduced bone mass in FR male mice, and administration of either active vitamin D analogue could increase bone mass even in IGF-I conditional knockout FR male mice. Taken together, conditions comparable to the female athlete triad are also a risk for male stress injuries, and low energy availability is upstream of gonadal dysfunction and osteoporosis in males. Active vitamin D analogues could serve as therapeutic or preventive options for stress injuries in men.
- Open Access
- 12 August 2022
- Published by Springer Nature in Research Square
TNFα-dependent mTOR activity is required for tenotomy-induced ectopic ossification in mice
Ectopic ossifications often occur in skeletal muscles or tendons following local trauma or internal hemorrhage, and occasionally cause severe pain that limits activities of daily living. However, mechanisms underlying their development remain unknown. Here we show that dissection of the Achilles tendon promotes ectopic ossification at dissection sites in wild-type mice. We observed mTOR activation at dissection sites, and development of ectopic ossification was significantly inhibited by administration of rapamycin, an mTOR inhibitor, to wild-type mice. Moreover, administration of the histamine 2 blocker cimetidine, which reportedly inhibits ectopic ossification in tendons, was not effective in inhibiting ectopic ossification in our models. The inflammatory cytokine TNFα reportedly stimulates mTOR signaling, and we show that TNFα-expressing F4/80-positive macrophages accumulate at dissection sites and that ectopic ossification of the Achilles tendon dissection was significantly inhibited in TNFα-deficient mice in vivo. We also show that ectopic ossification is significantly inhibited by administration of either celecoxib or loxoprofen, both anti-inflammatory agents, in wild-type mice. Finally, we report that mTOR activation by Achilles tendon tenotomy is inhibited in TNFα-deficient mice. Thus, the TNFα-mTOR axis could be targeted therapeutically to prevent trauma-induced ectopic ossification in tendons.
- 12 August 2022
- Published by Springer Nature in Research Square
Open AccessTNFα-dependent mTOR activity is required for tenotomy-induced ectopic ossification in mice
Ectopic ossifications often occur in skeletal muscles or tendons following local trauma or internal hemorrhage, and occasionally cause severe pain that limits activities of daily living. However, mechanisms underlying their development remain unknown. Here we show that dissection of the Achilles tendon promotes ectopic ossification at dissection sites in wild-type mice. We observed mTOR activation at dissection sites, and development of ectopic ossification was significantly inhibited by administration of rapamycin, an mTOR inhibitor, to wild-type mice. Moreover, administration of the histamine 2 blocker cimetidine, which reportedly inhibits ectopic ossification in tendons, was not effective in inhibiting ectopic ossification in our models. The inflammatory cytokine TNFα reportedly stimulates mTOR signaling, and we show that TNFα-expressing F4/80-positive macrophages accumulate at dissection sites and that ectopic ossification of the Achilles tendon dissection was significantly inhibited in TNFα-deficient mice in vivo. We also show that ectopic ossification is significantly inhibited by administration of either celecoxib or loxoprofen, both anti-inflammatory agents, in wild-type mice. Finally, we report that mTOR activation by Achilles tendon tenotomy is inhibited in TNFα-deficient mice. Thus, the TNFα-mTOR axis could be targeted therapeutically to prevent trauma-induced ectopic ossification in tendons.
- Open Access
- 1 July 2022
- Published by Springer Nature in Research Square
The Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis
Background Rheumatoid arthritis (RA) is a disease characterized by chronic joint inflammation, pain and joint destruction, leading to alteration in activities of daily living, yet pathological mechanisms underlying the condition are not fully clarified. To date, various therapeutic agents have been developed as RA therapy including DMARDs and/or biological agents that target inflammatory cytokines or inhibit JAK. Here we asked whether inhibiting signal transducer and activator of transcription 3 (Stat3) activity would antagonize RA. Methods Stat3 forms dimers when activated and undergoes nuclear translocalization; thus we screened approximately 4.9 million small compounds as potential blockers of protein-protein interactions required for Stat3 dimerization using in silico screening. We then tested candidate Stat3-inhibiting activity in vitro by analyzing expression of IL-6, a Stat3 target, in compound-treated fibroblasts. We also analyzed expression of RANKL, a cytokine essential for osteoclastogenesis, in vitro. We then evaluated anti-arthritis effects of candidate compounds in vivo in collagen-induced arthritis model mice. Effects of the candidate compounds on inhibiting Stat3 phosphorylation and nuclear localization following IL-6 stimulation of fibroblasts were analyzed by an immune histocochemical analysis as well as western blotting. Results We identified 15 as strong candidates as potential blockers of protein-protein interactions required for Stat3 dimerization using in silico screening from approximately 4.9 million small compounds. Four of the 15 significantly inhibited IL-6 as well as RANKL expression induced by IL-6. One compound, F0648-0027, significantly inhibited arthritis development without apparent adverse effects. F0648-0027 also significantly blocked Stat3 phosphorylation and nuclear localization following IL-6 stimulation of fibroblasts. Conclusions These data suggest that Stat3 is a target for RA, and that F0648-0027 could serve as a therapeutic reagent against the condition.
- 1 July 2022
- Published by Springer Nature in Research Square
Open AccessThe Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis
Background Rheumatoid arthritis (RA) is a disease characterized by chronic joint inflammation, pain and joint destruction, leading to alteration in activities of daily living, yet pathological mechanisms underlying the condition are not fully clarified. To date, various therapeutic agents have been developed as RA therapy including DMARDs and/or biological agents that target inflammatory cytokines or inhibit JAK. Here we asked whether inhibiting signal transducer and activator of transcription 3 (Stat3) activity would antagonize RA. Methods Stat3 forms dimers when activated and undergoes nuclear translocalization; thus we screened approximately 4.9 million small compounds as potential blockers of protein-protein interactions required for Stat3 dimerization using in silico screening. We then tested candidate Stat3-inhibiting activity in vitro by analyzing expression of IL-6, a Stat3 target, in compound-treated fibroblasts. We also analyzed expression of RANKL, a cytokine essential for osteoclastogenesis, in vitro. We then evaluated anti-arthritis effects of candidate compounds in vivo in collagen-induced arthritis model mice. Effects of the candidate compounds on inhibiting Stat3 phosphorylation and nuclear localization following IL-6 stimulation of fibroblasts were analyzed by an immune histocochemical analysis as well as western blotting. Results We identified 15 as strong candidates as potential blockers of protein-protein interactions required for Stat3 dimerization using in silico screening from approximately 4.9 million small compounds. Four of the 15 significantly inhibited IL-6 as well as RANKL expression induced by IL-6. One compound, F0648-0027, significantly inhibited arthritis development without apparent adverse effects. F0648-0027 also significantly blocked Stat3 phosphorylation and nuclear localization following IL-6 stimulation of fibroblasts. Conclusions These data suggest that Stat3 is a target for RA, and that F0648-0027 could serve as a therapeutic reagent against the condition.
- Open Access
- 15 January 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (1) , 82
Hao1 Is Not a Pathogenic Factor for Ectopic Ossifications but Functions to Regulate the TCA Cycle In Vivo
Ossification of the posterior longitudinal ligament (OPLL), a disease characterized by the ectopic ossification of a spinal ligament, promotes neurological disorders associated with spinal canal stenosis. While blocking ectopic ossification is mandatory to prevent OPLL development and progression, the mechanisms underlying the condition remain unknown. Here we show that expression of hydroxyacid oxidase 1 (Hao1), a gene identified in a previous genome-wide association study (GWAS) as an OPLL-associated candidate gene, specifically and significantly decreased in fibroblasts during osteoblast differentiation. We then newly established Hao1-deficient mice by generating Hao1-flox mice and crossing them with CAG-Cre mice to yield global Hao1-knockout (CAG-Cre/Hao1flox/flox; Hao1 KO) animals. Hao1 KO mice were born normally and exhibited no obvious phenotypes, including growth retardation. Moreover, Hao1 KO mice did not exhibit ectopic ossification or calcification. However, urinary levels of some metabolites of the tricarboxylic acid (TCA) cycle were significantly lower in Hao1 KO compared to control mice based on comprehensive metabolomic analysis. Our data indicate that Hao1 loss does not promote ectopic ossification, but rather that Hao1 functions to regulate the TCA cycle in vivo.
- 15 January 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (1) , 82
Open AccessHao1 Is Not a Pathogenic Factor for Ectopic Ossifications but Functions to Regulate the TCA Cycle In Vivo
Ossification of the posterior longitudinal ligament (OPLL), a disease characterized by the ectopic ossification of a spinal ligament, promotes neurological disorders associated with spinal canal stenosis. While blocking ectopic ossification is mandatory to prevent OPLL development and progression, the mechanisms underlying the condition remain unknown. Here we show that expression of hydroxyacid oxidase 1 (Hao1), a gene identified in a previous genome-wide association study (GWAS) as an OPLL-associated candidate gene, specifically and significantly decreased in fibroblasts during osteoblast differentiation. We then newly established Hao1-deficient mice by generating Hao1-flox mice and crossing them with CAG-Cre mice to yield global Hao1-knockout (CAG-Cre/Hao1flox/flox; Hao1 KO) animals. Hao1 KO mice were born normally and exhibited no obvious phenotypes, including growth retardation. Moreover, Hao1 KO mice did not exhibit ectopic ossification or calcification. However, urinary levels of some metabolites of the tricarboxylic acid (TCA) cycle were significantly lower in Hao1 KO compared to control mice based on comprehensive metabolomic analysis. Our data indicate that Hao1 loss does not promote ectopic ossification, but rather that Hao1 functions to regulate the TCA cycle in vivo.
- Open Access
- 1 December 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 582, 111-117
Smad2 and Smad3 expressed in skeletal muscle promote immobilization-induced bone atrophy in mice
- 1 December 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 582, 111-117
Open AccessSmad2 and Smad3 expressed in skeletal muscle promote immobilization-induced bone atrophy in mice
- 16 July 2021
- Published by SAGE Publications in Stem Cells and Development
- Vol. 30 (14) , 725-735
CD271 + CD51 + PALLADIN − Human Mesenchymal Stromal Cells Possess Enhanced Ossicle-Forming Potential
Human mesenchymal stem/stromal cells (hMSCs), when engrafted into immunodeficient mice, can form ectopic bone organs with hematopoietic stem cell (HSC) supportive functions. However, the ability to do so, through a cartilage intermediate, appears limited to 30% of donor bone marrow samples. In this study, we characterize the heterogeneous nature of hMSCs and their ability to efficiently form humanized ossicles observed in “good donors” to correlate with the frequency and functionality of chondrocyte progenitors. Flow cytometry of putative hMSC markers was enriched in the CD271 + CD51 + stromal cell subset, which also possessed enhanced hMSC activity as assessed by single-cell colony-forming unit fibroblast (CFU-F) and undifferentiated mesensphere formation. Transcriptome analysis of CD271 + cells presented upregulation of chondrogenesis-/osteogenesis-related genes and HSC/niche maintenance factors such as C-X-C motif chemokine 12 (CXCL12) and ANGIOPOIETIN 1 . Among the candidate genes selected to enrich for subsets with greater chondrogenic ability, cells negative for the actin cross-linker PALLADIN displayed the greatest CFU-F potential. Our study contributes to a better characterization of ossicle-forming hMSCs and their efficient isolation for the optimized engineering of human bone organs.
- 16 July 2021
- Published by SAGE Publications in Stem Cells and Development
- Vol. 30 (14) , 725-735
CD271 + CD51 + PALLADIN − Human Mesenchymal Stromal Cells Possess Enhanced Ossicle-Forming Potential
Human mesenchymal stem/stromal cells (hMSCs), when engrafted into immunodeficient mice, can form ectopic bone organs with hematopoietic stem cell (HSC) supportive functions. However, the ability to do so, through a cartilage intermediate, appears limited to 30% of donor bone marrow samples. In this study, we characterize the heterogeneous nature of hMSCs and their ability to efficiently form humanized ossicles observed in “good donors” to correlate with the frequency and functionality of chondrocyte progenitors. Flow cytometry of putative hMSC markers was enriched in the CD271 + CD51 + stromal cell subset, which also possessed enhanced hMSC activity as assessed by single-cell colony-forming unit fibroblast (CFU-F) and undifferentiated mesensphere formation. Transcriptome analysis of CD271 + cells presented upregulation of chondrogenesis-/osteogenesis-related genes and HSC/niche maintenance factors such as C-X-C motif chemokine 12 (CXCL12) and ANGIOPOIETIN 1 . Among the candidate genes selected to enrich for subsets with greater chondrogenic ability, cells negative for the actin cross-linker PALLADIN displayed the greatest CFU-F potential. Our study contributes to a better characterization of ossicle-forming hMSCs and their efficient isolation for the optimized engineering of human bone organs.
- 28 April 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 558, 183-188
Synoviolin is not a pathogenic factor for auto-inflammatory diseases
- 28 April 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 558, 183-188
Synoviolin is not a pathogenic factor for auto-inflammatory diseases